Targeting PCSK9 in clinical practice: Guidance & future

Targeting PCSK in clinical practice Guidance  future
10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME
  • Overview

    Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

  • Educational information

    This lecture by prof. John Kastelein was part of a CME accredited symposium: "PCSK9 inhibition: Science, outcomes and guidance" held at ESC 2018 in Munich, Germany.

  • Faculty

    Prof. John Kastelein , MD – Professor of Medicine, Department of Vascular Medicine at the Amsterdam University Medical Centers (AUMC) of the University of Amsterdam, The Netherlands, where he holds the Strategic Chair of Genetics of Cardiovascular Disease

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Amgen and Sanofi-Regeneron.

    The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free